Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11230506 | 0.84 | LMNA (0.62) | LMNAALDH1A1MAPTSMN1; SMN2POLB | |
| SCHEMBL752500 | 0.82 | MAPT (0.64) | LMNAALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL6505055 | 0.82 | LMNA (0.44) | LMNAALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL3143253 | 0.81 | LMNA (0.67) | LMNAALDH1A1MAPTSMN1; SMN2POLB | |
| SCHEMBL6650881 | 0.81 | MAPT (0.55) | LMNAALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3143262 | 0.81 | LMNA (0.67) | LMNAALDH1A1MAPTSMN1; SMN2POLB | |
| SCHEMBL15088714 | 0.81 | LMNA (0.66) | LMNAALDH1A1MAPTSMN1; SMN2POLB | |
| SCHEMBL11765445 | 0.80 | LMNA (0.57) | LMNAALDH1A1MAPTPOLBMEN1 | |
| SCHEMBL1827529 | 0.80 | LMNA (0.56) | LMNAALDH1A1MAPTSMN1; SMN2POLB | |
| SCHEMBL12933644 | 0.79 | LMNA (0.55) | LMNAALDH1A1MAPTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113366-A1 | Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses | UNIVERSITE LOUIS PASTEUR (ETABLISSEMENT PUBLIC A CARACTERE SCIENTIFIQUE, CULTUREL ET PROFESSIONNEL) (FR) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113366-A1 | Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses | GABRB1, GABRA1, GABRA5 | LMNA 2279/4885ALDH1A1 590/4885MAPT 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.